Canine Pai 1 Recombinant Stable Mutant

• Description:

  Canine Pai 1 Recombinant Stable Mutant_x000D_ Catalog number: B2017147_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 100 ug_x000D_ Molecular Weight or Concentration: N/A_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80C_x000D_ Keywords: Canine Pai 1 Recombinant Stable Mutant_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Masunaga Y, Asakura S, Muto S, Ando Y, Homma S, Kusano E, Matsuda M, Asano Y. Multimeric vitronectin in ascites is involved in fibroblast spreading of EPS in patients on CAPD therapy Clin Exp Nephrol. 2003 Jun;7(2):150-6._x000D_ 2: Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, Harada S, Seiki M, Sato H. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth Oncogene. 2000 Mar 30;19(14):1764-71._x000D_ 3: Zoulikha M, Xiao Q, Boafo GF, Sallam MA, Chen Z, He W. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome Acta Pharm Sin B. 2022 Feb;12(2):600-620._x000D_ 4: Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis J Pharmacol Exp Ther. 2005 Aug;314(2):710-6._x000D_ 5: Wong CJ, Koch M, Behling-Kelly EL. Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs Res Vet Sci. 2017 Apr;111:1-8._x000D_ 6: Reilly CF, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism Circulation. 1991 Jul;84(1):287-92._x000D_ 7: Sodek J, Overall CM. Matrix metalloproteinases in periodontal tissue remodelling Matrix Suppl. 1992;1:352-62._x000D_ 8: Kuleš J, Gotić J, Mrljak V, Barić Rafaj R. Blood markers of fibrinolysis and endothelial activation in canine babesiosis BMC Vet Res. 2017 Mar 31;13(1):82._x000D_ 9: Miyazaki H, Sai H, Ohmizu H, Murakami J, Ohtani A, Ogiku T. Synthesis and evaluation of 1,4-diphenylbutadiene derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) production Bioorg Med Chem. 2010 Mar 1;18(5):1968-79._x000D_ 10: Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment Semin Arthritis Rheum. 1999 Feb;28(4):211-67. _x000D_ _x000D_ Products Related to Canine Pai 1 Recombinant Stable Mutant can be found at Proteins

• Short Description:

  Catalog Number: B2017147 (100 ug)_x000D_ Canine Pai 1 Recombinant Stable Mutant is a high quality genetically modified form of the canine Pai 1 protein that has been engineered to be stable and have specific properties for research or therapeutic purposes. Pai 1 is a protein involved in blood clotting and inflammation, and mutations in this protein can lead to various health conditions. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3